Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. It is expected to be worth USD 2.1

Access 105

Access Research and Development Pharmaceutical Therapy 105

Veriheal

JUNE 22, 2021

“Cannabis should remain illegal because more research is needed. We are not fully aware of the consequences of cannabis legalization because there are not enough studies to solidify its therapeutic uses” Yet the same individuals spewing this crap are the ones that stand in the way of progress.

DEA 59

DEA Access Therapy Cannabinoids 59

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Exclusive licensing agreement with leading global cannabis company (“Canopy Growth”). Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Our lead product, ANEB-001, has the potential to rapidly reverse the effects of acute cannabinoid intoxication, a relatively unknown yet serious affliction that sends more than 5,000 Americans to the hospital emergency department every day.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

FEBRUARY 7, 2023

Under this new program, Protonify will provide cannabis researchers with complimentary access to its high-purity, pharmaceutical-grade cannabinoid ingredients including THC concentrate and THCA isolate.

Pharmaceutical 52

Pharmaceutical Cannabinoids Concentrates THC 52

Cannabis Law Report

JUNE 1, 2022

This acquisition will accelerate Khiron’s growth in Europe by controlling the complete value chain for its products and gaining direct access to German pharmacies. Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

Cannabis Law Report

JULY 28, 2021

On 1 June 2021, the Group announced an agreement with Voisin Consulting SARL (“VC”), a life sciences consultancy comprising over 200 professionals in the UK, US and India, with expertise in medical devices, cannabinoids, neurological disorders and addictions.

Cannabinoids 105

Cannabinoids Clinical Trials Safety Medicine 105

Cannabis Law Report

OCTOBER 27, 2021

a vertically integrated provider of safe and sustainable specialty ingredients, today announced that it has successfully completed commercial-scale, fermentation-based production campaigns for its Lygos CBx cannabinoid products, including CBG (cannabigerol), CBC (cannabichromene), CBD (cannabidiol), and CBDA (cannabidiolic acid).

Cannabinoids 52

Cannabinoids Pharmaceutical Agriculture CBD 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. Medical cannabis costs family £4,000 a month to help teenager. What is Epidyolex?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Veriheal

AUGUST 9, 2023

Recent research reaffirms earlier studies that claim that certain non-marijuana plants contain similar compounds found in cannabis, often called cannabinoids. Presently, CBD is inarguably the most acceptable compound in cannabis. Some have even explored it for its aphrodisiac potential.

CBD 93

CBD Cannabinoids THC Extraction 93

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

The Cannigma

JUNE 2, 2022

Ever wondered how cannabinoids like THC or CBD affect your blood? It may seem like a weird question, but it is a vitally important one for anyone taking anticoagulant medications and considering using cannabis. The short answer is – no, in most cases cannabinoids do not seem to act as strong blood thinners.

Blood Pressure 112

Blood Pressure Cannabinoids Patients THC 112

Veriheal

AUGUST 13, 2020

In talking about cannabis and its uses, a lot of attention is always paid to THC, the most well known cannabinoid in the cannabis plant. If you’ve been paying attention to the cannabis industry in the last year or so, you’re probably also very aware of another compound. The Father of Cannabis Research.

Cannabinoids 98

Cannabinoids Chronic Pain Sleep Pharmaceutical 98

United Patients Group

MAY 17, 2023

Some researchers believe that cannabinoids may help people with ASD manage anxiety and stress by increasing their ability to focus and pay attention. Cannabinoids have been shown to help people with autism manage anxiety and stress.

Sleep 80

Sleep Cannabinoids Patients CBD 80

Cannabis Law Report

SEPTEMBER 8, 2021

Key Transaction Details: The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a long-term partnership with Epsilon, for exclusive access to the Epsilon’s GMP Manufacturing Facility in Southport , Queensland Australia (the “ Southport Facility ‘).

Access 97

Access Research and Development Medicine THC 97

PrestoDoctor

SEPTEMBER 6, 2023

The legalization of cannabis in some countries and states has brought about significant changes in the healthcare industry. However, with the increasing popularity of cannabis, many people are turning to marijuana as a safer and better alternative for pain management.

Chronic Pain 105

Chronic Pain Research and Development Patients Cannabis 105

Cannabis Law Report

DECEMBER 22, 2021

With growing interest in sustainable and bio-based cannabinoids, and after completing a strategic review of Hyasynth including their intellectual property (IP) and R&D platforms, Organigram remains excited about Hyasynth’s future and growth plans. NASDAQ: OGI), (TSX: OGI), the parent company of Organigram Inc. million in October 2020.

Cannabinoids 52

Cannabinoids Research and Development Events Pharmaceutical 52

Cannabis Law Report

SEPTEMBER 7, 2022

The acquisition by Ramm provides access to HemPoland’s distribution network, recognized premium brands, hemp oil extraction technologies, and an additional synergistic foothold into the European market following the acquisition of Sicily-based Canapar Corp. About RAMM Pharma Corp.

Hemp 59

Hemp Pharmaceutical Extraction Cannabinoids 59

Veriheal

SEPTEMBER 27, 2021

The United Kingdom’s Multiple Sclerosis (MS) Society has taken a stand against restricted access to medical cannabis in the country. The society launched a campaign with the hashtag #ApprovedButDenied protesting the difficulty so many patients have faced attempting to obtain medical cannabis. ApprovedButDenied.

Treatment 98

Treatment Patients Access Research and Development 98

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Work with U.S. Mike Beyer.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JULY 5, 2021

Bod Australia (ASX:BDO) has reported record medicinal cannabis sales growth during the 2020/21 financial year. Patterson anticipates continued increased demand for Bod’s medical cannabis products in the time ahead, also mentioning operations in the UK are continuing to scale up.

Cannabinoids 95

Cannabinoids CBD Pharmaceutical Access 95

Veriheal

AUGUST 2, 2023

That’s right; cannabis could be very beneficial in your mission to remain mindful while parenting. Let’s explore five reasons why many parents are choosing to utilize cannabis as a tool in their parenting repository. Cannabis can be a helpful tool for mindful parenting when you want to let loose a little.

Microdosing 98

Microdosing Consumption Pharmaceutical Cannabis 98

Veriheal

SEPTEMBER 23, 2021

Cannabis; it’s smoking hot right now. Current statistics from the Anthenum Collective show that more than 67% of Americans believe cannabis should be legal, and legal cannabis sales are expected to achieve a value of $73.6 cannabis industry is estimated to be worth $61 billion as of 2021.

Business 97

Business Access Cannabis Therapy 97

Veriheal

SEPTEMBER 20, 2021

Now, the latest trend among folks living in states without access to legal cannabis is THC-O. While THC-O could be considered a cannabinoid, it’s better described as a compound due to being synthetically derived from hemp. Cannabinoid therapies and research have started to advance across the United States.

THC 98

THC Cannabinoids Vaping Hemp 98

Cannabis Law Report

FEBRUARY 18, 2022

We are one of the first to successfully complete a commercial shipment of Colombian-manufactured high-CBD pharmaceutical product to Germany available for patients in pharmacies under prescription. In addition, this reflects our increasing know-how to comply with complex and sophisticated regulatory and quality frameworks.

Extraction 52

Extraction Pharmaceutical Patients Cannabinoids 52

Cannabis Law Report

APRIL 29, 2022

to expand its capabilities into Europe’s largest medical cannabis market and gain access to around 20,000 pharmacies in Germany through its affiliate Clever Leaves Germany GmbH. We will distribute medical cannabis products, manufactured in compliance with local guidelines, from our production facilities in Portugal and Colombia.”.

Pharmaceutical 52

Pharmaceutical Compliance Compliance Cannabinoids 52

Cannabis Law Report

FEBRUARY 27, 2022

Melbourne-based medicinal cannabis product developer Incannex (ASX: IHL) has officially landed on the US stock exchange Nasdaq, hoping its dual listing will attract an expanded pool of investors. Listing on Nasdaq will help increase our visibility with international investors and clinical research facilities.

Medicine 52

Medicine Research and Development Therapy Pharmaceutical 52

Cannabis Law Report

MARCH 29, 2022

A Flurry of Cannabis M&A Activity in 2022. That is the best way to describe the pace of the cannabis industry in 2022. We are witnessing a torrid start as it relates to cannabis M&A. On March 23 rd , Cresco Labs become the market leader in cannabis with the acquisition of Columbia Care. By Robert Hoban.

Pharmaceutical 52

Pharmaceutical Cannabinoids Data Policy 52

Veriheal

OCTOBER 13, 2020

Cannabis has been identified as an effective alternative treatment for some gastrointestinal disorders…but does that include IBD and IBS? . Cannabis for GI Pathologies . A clinical study done by Steele Clark Smith and Mark Wagner found that cannabis consumption led to improved IBS symptoms as a whole. What is IBD?

Digestion 123

Digestion Treatment Conditions Research and Development 123

The Cannigma

FEBRUARY 4, 2021

When it comes to cannabis and the struggle for legalization, improving access, and changing hearts and minds, advocates often find themselves up against decades-old myths, misconceptions, and stereotypes that have been delivered from authoritative sources for so long that for many people they supplant the truth. grandbrothers/123rf).

THC 145

THC Cannabinoids Blood Pressure Conditions 145

The Cannigma

JUNE 14, 2021

For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. The BRC is among the dozens of organizations that have received preliminary approval from the DEA to cultivate cannabis. Shutterstock).

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Cannabis Law Report

SEPTEMBER 14, 2022

Cannabis Health reports. The cannabis-based treatment, Sativex, will now be available via NHS prescription in Scotland, to treat spasticity in MS patients. Although a limited number of people have been able to access it via the Peer Approved Clinical System (PACS) Tier 2 individual patient treatment request process.

Treatment 52

Treatment Access Patients Medicine 52

Cannabis Law Report

JUNE 17, 2021

NASDAQ: CLVR) said it has entered into an active pharmaceutical ingredient supply agreement with CBD Life Holding SAPI de CV, an emerging leader in the Mexican cannabis industry which offers a line of CBD Wellness and consumer products and medical cannabis products which are under development. Clever Leaves Holdings Inc.

CBD 111

CBD Pharmaceutical Compliance Compliance 111

Cannabis Law Report

JULY 26, 2021

VANCOUVER, British Columbia, July 26, 2021 (GLOBE NEWSWIRE) — BC Craft Supply Co Ltd., ( CSE: CRFT ) (“ CRFT ” or the “ Company ”), a diversified wellness company advancing cannabinoid and psychedelic innovation and psychotherapy, is pleased to announce that its subsidiary, FeelWell Brands Inc. BC Craft Supply Co Ltd.

Events 105

Events Cannabinoids Advocacy Cannabis 105

Cannabis Law Report

MAY 8, 2022

This time last year the Legalise Cannabis Party in Australia was comprised of a number of disparate state-based organisations. I have an extensive background in healthcare and have worked in the community, aged care and palliative care sectors as well the corporate (pharmaceutical and insurance) sectors. WHAT MADE YOU STAND?

Education 98

Education Medicine Cannabinoids Programs 98

The Cannigma

JUNE 1, 2021

While France has long been said to have the highest number of cannabis users per capita in Europe, it has long lagged behind its western Europe neighbors when it comes to tolerance of the plant. Marijuana is not legal in France, and the country is seen as having some of the strictest cannabis policies in western Europe. Shutterstock.

Law 113

Law Epilepsy Programs Patients 113

Cannabis Law Report

JANUARY 10, 2020

All four members of the Editorial Board have volunteered their time to offer independent advice and assistance in order to support Medical Cannabis Network ’s commitment to providing up to date content regarding the cannabis industry. Deepak Anand is recognised as a thought leader in the global cannabis space. Anne Schlag.

Research and Development 59

Research and Development Supply Chain Pharmaceutical Medicine 59